Rani Therapeutics Holdings (RANI) Stock Overview
Operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
RANI Community Fair Values
Create NarrativeSee what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.
Rani Therapeutics Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.42 |
| 52 Week High | US$3.87 |
| 52 Week Low | US$0.39 |
| Beta | -0.015 |
| 1 Month Change | 386.50% |
| 3 Month Change | 381.65% |
| 1 Year Change | -4.17% |
| 3 Year Change | -58.43% |
| 5 Year Change | n/a |
| Change since IPO | -78.05% |
Recent News & Updates
Recent updates
RT-114 And Pill Technology Will Transform Obesity Treatments
RaniPill technology and RT-114 partnership position Rani Therapeutics to capture significant market share and boost future revenue.Is Rani Therapeutics Holdings (NASDAQ:RANI) Using Too Much Debt?
Feb 07
Does Rani Therapeutics Holdings (NASDAQ:RANI) Have A Healthy Balance Sheet?
Jul 16Is Rani Therapeutics Holdings (NASDAQ:RANI) Weighed On By Its Debt Load?
Mar 20Rani Therapeutics enters $45M loan agreement to support advancement and pipeline development
Aug 08We're Not Very Worried About Rani Therapeutics Holdings' (NASDAQ:RANI) Cash Burn Rate
Feb 13Shareholder Returns
| RANI | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 392.5% | 0.2% | -0.1% |
| 1Y | -4.2% | -5.4% | 16.6% |
Return vs Industry: RANI exceeded the US Pharmaceuticals industry which returned -5.9% over the past year.
Return vs Market: RANI underperformed the US Market which returned 16.7% over the past year.
Price Volatility
| RANI volatility | |
|---|---|
| RANI Average Weekly Movement | 70.5% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: RANI's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: RANI's weekly volatility has increased from 38% to 70% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 106 | Talat Imran | www.ranitherapeutics.com |
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-116 which is in discovery stage for the treatment of obesity; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions.
Rani Therapeutics Holdings, Inc. Fundamentals Summary
| RANI fundamental statistics | |
|---|---|
| Market cap | US$204.83m |
| Earnings (TTM) | -US$29.69m |
| Revenue (TTM) | US$1.20m |
Is RANI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RANI income statement (TTM) | |
|---|---|
| Revenue | US$1.20m |
| Cost of Revenue | US$0 |
| Gross Profit | US$1.20m |
| Other Expenses | US$30.89m |
| Earnings | -US$29.69m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.62 |
| Gross Margin | 100.00% |
| Net Profit Margin | -2,473.83% |
| Debt/Equity Ratio | -188.2% |
How did RANI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/22 19:22 |
| End of Day Share Price | 2025/10/22 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Rani Therapeutics Holdings, Inc. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Geoffrey Meacham | BofA Global Research |
| Edward Nash | Canaccord Genuity |
| Mitchell Kapoor | H.C. Wainwright & Co. |